Business
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
NEW YORK, March 24, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of
About this update from Relmada Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, March 24, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Judy Caron, Ph.D., as Vice President of Drug Development. Dr. Caron has 30 years of experience in biopharmaceutical development.\n\n \n \n \n \n \n \n\n \nDr. Caron joins Relmada from Neurana Pharmaceuticals, a privately-held, clinical stage, biopharmaceutical company focused on the treatment of neuromuscular conditions. Dr. Caron co-founded the company in 2012 and served as Chief Operating Officer (COO) and Head of Clinical Development. Her responsibilities included project management, clinical development, chemistry and pharmaceutical development, and regulatory operations. Previously, Dr. Caron was COO and a partner at BioNevia Pharmaceuticals, LLC, from 2008-2014. Prior to this, she served in increasingly senior drug development-related roles as Vice President CNS Program Director at Sepracor Inc from 1997-2008. At Sepracor, Dr. Caron directed several CNS projects, including the development and approval of Lunesta® in the U.S. and Japan. She began her career at Sandoz Pharmaceuticals where she was Project Coordination Manager. Dr. Caron holds a Ph.D. in molecular genetics from Emory University, an M.S. degree in genetics from Ohio State University and a B.S. degree in biology from Cleveland State University.\n\"Dr. Caron has extensive CNS drug development experience,\" said Thomas Wessel, Head of Research and Development at Relmada. \"We are thrilled to add someone of Judy's caliber to our senior management team. Dr. Caron will be an instrumental team member to further advance REL-1017 in the clinic. This agent has the potential to become an important oral and rapid-acting adjunctive treatment in patients with major depression, and Judy will provide critical support to our team for the next steps in clinical development and the regulatory review process.\"\n\"I am delighted to join Relmada to continue the development of REL-1017, which could offer a compelling new treatment option to the millions of patients suffering from depression,\" said Dr. Caron. \"REL-1017 has previously shown rapid, statistically and clinically meaningful antidepressant activity, in conjunction with a favorable tolerability...